We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.05 | 1.47% | 3.45 | 0.00 | 16:35:23 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.90 | 4.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 5.03M | -2.44M | -0.0083 | -4.10 | 10.04M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 3.45 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 16/5/2024 | 13:10 | UK RNS | Proteome Sciences PLC Result of AGM |
| 16/5/2024 | 12:23 | ALNC |  IN BRIEF: Proteome Sciences promises AGM return to growth in 2024 |
| 16/5/2024 | 07:00 | UK RNS | Proteome Sciences PLC AGM Statement |
| 26/4/2024 | 11:18 | ALNC | Proteome wins GBP500,000 deal to supply mass spectrometry services |
| 26/4/2024 | 07:00 | UK RNS | Proteome Sciences PLC Contract Win |
| 10/4/2024 | 11:26 | ALNC | Proteome Sciences shares drop as revenue plunges and swings to loss |
| 10/4/2024 | 07:00 | UK RNS | Proteome Sciences PLC Final Results |
| 02/1/2024 | 10:52 | ALNC | IN BRIEF: Proteome Sciences says San Diego lab now fully operational |
| 02/1/2024 | 07:00 | UKREG | Proteome Sciences PLC Completion of new facility in San Diego |
| 30/11/2023 | 09:42 | ALNC | Proteome Sciences shares drop as cuts annual revenue outlook |
Proteome Sciences (PRM) Share Charts1 Year Proteome Sciences Chart |
|
1 Month Proteome Sciences Chart |
Intraday Proteome Sciences Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/7/2024 | 12:44 | Proteome Sciences leading Alzheimer's technology. | 92,991 |
| 22/7/2024 | 11:23 | Proteome, what next? (moderated) | 59,775 |
| 08/3/2024 | 19:33 | Does Fgnoms really have to say the same thing all the time thread | 26 |
| 13/5/2020 | 19:36 | Only worth 3p on fundamentals.... | 10 |
| 28/4/2020 | 07:22 | Proteome Sciences plc, A Three Horse Race for the Month of May. | 4,854 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Proteome Sciences Daily Update Proteome Sciences Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome Sciences was 3.40p.Proteome Sciences currently has 295,182,056 shares in issue. The market capitalisation of Proteome Sciences is £10,036,190. Proteome Sciences has a price to earnings ratio (PE ratio) of -4.10. This morning PRM shares opened at - |
Posted at 22/7/2024 12:27 by sandcrab2 The excellent Fgnoms covered this 13 years ago“fgnoms30 Apr '11 - 10:28 - 14 of 26 0 0 0 Well here we are at the end of April and still no commercial money-making contracts have been signed. CJP at the time of the money raising reiterated break even for 2010, which would have required a few such contracts to have been signed in say late Q3 2010. So seven months on and NO such deals have been signed. I guess the important question is why? Of course we have suffered the same sorry story for the last 4 years on stroke. Yes 4 years ago contracts were imminent and apparently still are but we haven't been told why they haven't been signed. The obvious explanation is that PRM stroke biomarkers together with other panel constituents don't work well enough and therefore a stroke panel cannot be commercialised. Remember all those companies testing the PRM stroke biomarkers - and absolutely nothing has resulted. I think it would now be reasonable to assume that stroke is dead. So what about AD. Yes we are now at the same stage as stroke was 4 years ago. Tests are being carried out - but this time by PRM itself. This indicates to me that none of the big boys have any faith whatsoever in PRM's AD biomarkers - especially since the Dutch revelation that Clusterin isn't a predictive biomarker. So why does PRM continue to lead us on that a commercial deal is just around the corner. I find this bizarre. As PRM is now carrying out its own tests on its own panel nobody is going to sign anything until the results are known - which will probably be in H1 2012. And even then it really isn't feasible that a final saleable AD working panel will only contain PRM biomarkers, is it? So in my view we are years away from a working AD panel. So where does all this optimism come from - cloud cuckoo land imho. So before my next post we will know the 2010 results - a complete disaster no doubt. A loss of nearly £5m compared with target breakeven. 2011 is also looking like another £5m loss as I don't believe any commercial contracts will be signed. 2012 may not be much better either and thats when the cash runs out. So what will the share price be when all this is revealed next month? A very far cry from anything the rampers are saying thats for sure.” |
Posted at 22/7/2024 10:51 by barry evans re 92987For the benefit of those that have the avatar goatherd filtered and will not have been able to view this (It is quite something): wasjobber 22 Jul '24 - 10:18 - 59772 of 59774 0 1 0 I wonder how high Proteome Sciences share price will rise after Randox announce the release of their clinical Stroke test in blood? pools2 22 Jul '24 - 10:31 - 59773 of 59774 0 0 0 wasjobber, PRM's share price should rise significantly after Randoz release their clinical Stroke test. It could also rise before the release date. wasjobber 22 Jul '24 - 10:43 - 59774 of 59774 0 0 0 Thanks pools2 |
Posted at 22/7/2024 10:31 by pools2 wasjobber,PRM's share price should rise significantly after Randoz release their clinical Stroke test. It could also rise before the release date. |
Posted at 22/7/2024 10:14 by wasjobber I wonder how high Proteome Sciences share price will rise after Randox announce the release of their clinical Stroke test in blood? |
Posted at 01/7/2024 15:03 by monte1 If only we could see a bit of revenue or share price creep eh? |
Posted at 19/6/2024 07:37 by goatherd peverill,You do not seem to understand PRM's tactics. They have a large number of patents. They are simply watching other people testing and using them for reaearch (for which a license is not required). Then when (and if :-( ) they start to use them clinically, they will step in and demand royalties. Of course they will not want to alert users too early, as the user might find different, non-PRM-patented, biomarkers; but if they wait until the user is heavily commited it should work. |
Posted at 26/4/2024 10:20 by wasjobber It looks like Proteome Sciences share price is turning to an uptrend. The eight month downtrend has just been broken to the upside. Richard Dennis hints at further big contracts to come this year.Of course, this is all peanuts compared to the Alzheimer's disease, cancer and stroke IP that will lead to a significantly increased share price. STRONG BUY |
Posted at 10/4/2024 10:02 by pools2 wasjobber,Thermo have been a long term partner of Proteome Sciences for 15 years, but I agree it'll be good to see Thermo taking a more prominent position. After reading the RNS this morning, the future looks brighter than ever. You've already mentioned what I think is probably the most significant RNS statement:- "It's very interesting that PRM are now openly stating that their patented Alzheimer's and cancer biomarkers may be critical to new diagnostics and treatment moving forward. STRONG BUY" It's very significant for Proteome Sciences to say that. The value of these biomarkers will be considerable and will project PRM into the £100 millions plus market cap. with ease. I think you are now correct, we are at a pivotal moment for the share price and investors buying now will achieve significant returns, possibly quicker than some may think. |
Posted at 28/3/2024 15:12 by barry evans PramBigear 3 Jul '06 - 20:11 - 38468 of 61525 0 0 0Give it a rest Goatherd! "However I find Peter's theories and posts far more likely than yours. You sit on the fence and bleat. He posts what he believes - it is simply up to his readers what they do. It is possible that you will cost posters vastly more than Peter ever will." Jeffian's logical posts are certainly as valid as "Peter's theories" and certainly could not COST posters more than Peter's ever will, for Jeffian's implicit message is "don't risk your cash" whilst Peter's is "fill yer boots". You can only lose money that you already have. Miss an opportunity, perhaps, but that is not a COST. jeffian3 Jul '06 - 22:59 - 38472 of 61525 0 0 0 Richard, As Pram points out, a potential profit foregone is not exactly the same as a loss! When Peter said on 27/1/04 "we can be sure that the value of PRM shares will soon far exceed the £8 that Tuco forecast in his recent post" and encouraged people to buy, the share price was around 215. If it fulfilled Peter's best expectations tomorrow by 5-bagging without any opportunity to buy on the way up....then people who took his advice then would just about break even while followers of the Bar Room Monkey tendency would be in the same boat. I call that even-stevens. If, on the other hand, Peter's best expectations are not met, some people out there are nursing a nasty loss. That also presupposes that there will be no opportunity to climb aboard when/if it becomes clear that the potential is being turned into £££ but this flies in the face of the evidence of most major long-term growth stories from Microsoft downwards as a glimpse at their share charts will show. To take your point of a 'potential' £53 valuation over time, other than how stinking rich you want to be, it doesn't matter much whether you climb aboard at 39, 45, 60, £1 or £2, you're still going to do OK. Obviously my approach is more risk-averse but it concerns me that Peter's posts, however honestly held his views, go beyond just presenting his argument to stating that it is only our own stupidity which prevents us from drawing the same conclusions and specifically encouraging people to buy - and they have. As you say, "it is simply up to his readers what they do" but it doesn't hurt to remind them of the alternatives. Having made a bit of money, I like 'not losing it' almost as much as making more! In a wider context, as ever PRM-ers are following parallel (but not necessarily convergent!) courses with those of a 'scientific' bent hanging on the perceived progress of the IP while the BRM's want evidence to back up the claims - made by the company itself since 2003 remember - that it can be converted into a highly cash-generative asset. I have seen this so may times with shares like SPS, NTX, TRK, GHT etc. which have all had flurries of excitement having unique technology which should have given them access to vast markets but they've overpromised and underdelivered and the City won't rate them until the £££'s roll in. It's the same with this one and, whilst you may not like me saying it, a glance at the chart shows that if I'm 'wrong' I'm not alone so I may be some use to you contra-cyclical types to show you how the wider market is thinking! Finally, Richard, in your obsession with traders/shorters, you tend to see everything in terms of 'Buy' or 'Sell' but there is a perfectly respectable position called 'Hold', which is what I've been doing since Feb 2000. Or "sitting on the fence" as you call it. Regards, Ian |
Posted at 07/3/2024 18:40 by wrighty41 The current CEO of PRM is proving herself to be uninspiring imo.I’m still hopeful we may see 6p+ on the share price this year but without any update from PRM on the forward looking revenue outlook for 2024 it’s difficult to say. We’ll get the FY results over next couple of months. The forward guidance will be critical for share price progress. W41 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
